Cyclin-dependent kinase inhibitor, P276-00, inhibits HIF-1α and induces G2/M arrest under hypoxia in prostate cancer cells

Prostate Cancer and Prostatic Diseases

Volumn 15, Issue 1, 2012, Pages 15-27

  Manohar, S M ^a   Padgaonkar, A A ^a   Jalota Badhwar, A ^a   Rao, S V ^a   Joshi, K S ^a  

^a Piramal Enterprises Limited   (India)

Author keywords

HIF 1 ; P276 00; PI3K

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INITIATION FACTOR 4E BINDING PROTEIN 1; P 276 00; PROTEIN KINASE B; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOASSAY; CELL CYCLE PROGRESSION; CELL HYPOXIA; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SCREENING; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HYPOXIA INDUCIBLE FACTOR 1 GENE; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; LUCIFERASE GENE; MALE; MIGRATION INHIBITION; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; CELL LINE, TUMOR; CELL MOVEMENT; CELL NUCLEUS; CELL PROLIFERATION; CYCLIN D1; DRUG SYNERGISM; FLAVONES; G2 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GENES, REPORTER; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LUCIFERASES; MALE; MICE; MICE, SCID; PROSTATIC NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN KINASE INHIBITORS; PROTEOLYSIS; RANDOM ALLOCATION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84857040751     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2011.51     Document Type: Article

References (45)

1. Sun Y-L, Liu Y-N, Huang Y-T, Pan S-L, Huang D-Y, Guh J-H et al. YC-1 inhibits HIF-1 expression in prostate cancer cells: contribution of Akt/NF-kB signaling to HIF-1a accumulation during hypoxia. Oncogene 2007; 26: 3941-3951. (Pubitemid 46884296)
2. Akakura N, Kobayashi M, Horiuchi I, Suzuki A, Wang J, Chen J et al. Constitutive expression of hypoxia-inducible factor-1a renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res 2001; 61: 6548-6554. (Pubitemid 32783263)
3. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D et al. Overexpression of hypoxia-inducible factor 1a in common human cancers and their metastases. Cancer Res 1999; 59: 5830-5835.
4. Newcomb EW, Lukyanov Y, Schnee T, Ali MA, Lan L, Zagzag D. Noscapine inhibits hypoxia-mediated HIF-1alpha expression and angiogenesis in vitro: a novel function for an old drug. Int J Oncol 2006; 28: 1121-1130.
5. Sommani P, Yamashita K, Miyoshi T, Tsunemine H, Kodaki T, Mori H et al. Inhibitory effect of 6-Formylpterin on HIF-1a protein accumulation. Biol Pharm Bull 2007; 30: 2181-2184. (Pubitemid 350097031)
6. Dong-Li Z, Liu L-Z, Shi X, Fang J, Jiang B-H. Benzo[a] pyrene-3,6-dione inhibited VEGF expression through inducing HIF-1a degradation. Biochem Biophys Res Commun 2007; 357: 517-523. (Pubitemid 46603161)
7. Bilton RL, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2003; 4: 437-447.
8. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/ phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000; 60: 1541-1545. (Pubitemid 30183422)
9. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF1-alpha) synthesis: novel mechanism for HIF-1- mediated vascular endothelial growth factor expression. Mol Cell Biol 2001; 21: 3995-4004. (Pubitemid 32476461)
10. Treins C, Giorgetti-Peraldi S, Murdaca J, Semenza GL, Van OE. Insulin stimulates hypoxia-inducible factor 1 through a phosphotidyl 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem 2002; 277: 27975-27981. (Pubitemid 34966746)
11. Joshi KS, Rathos MJ, Joshi RD, Sivakumar M, Mascarenhas M, Kamble S et al. In vitro antitumor properties of a novel cyclindependent kinase inhibitor, P276-00-00. Mol Cancer Ther 2007; 6: 918-925. (Pubitemid 46554561)
12. Joshi KS, Rathos MJ, Mahajan P, Wagh V, Shenoy S, Chile S et al. P276-00-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther 2007; 6: 926-934. (Pubitemid 46554562)
13. Rapisarda A, Uranchimeg B, Scudiero DA, Selby M, Sausville EA, Shoemaker RH et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathways. Cancer Res 2002; 62: 4316-4324. (Pubitemid 34827288)
14. Zundel W, Schindler C, Haas-Kogan D, Koong A, Kaper F, Chen E. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 2000; 14: 391-396. (Pubitemid 30131884)
15. Chen EY, Mazure NM, Cooper JA, Giaccia AJ. Hypoxia activates a platelet-derived growth factor receptor/phosphatidylinositol 3-kinase/Akt pathway that results in glycogen synthase kinase-3 inactivation. Cancer Res 2001; 61: 2429-2433. (Pubitemid 32685819)
16. Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002; 22: 7004-7014.
17. Li M-H, Miao Z-H, Tan W-F, Yue J-M, Zhang X-W, Ding J. Pseudolaric acid B inhibits angiogenesis and reduces hypoxiainducible factor 1a by promoting proteasome-mediated degradation. Clin Cancer Res 2004; 10: 8266-8274. (Pubitemid 40053386)
18. Kong D, Park E-J, Stephen AG, Calvani M, Cardellina JH, Monks A et al. Echinomycin, a small-molecule inhibitor of hypoxiainducible factor-1 DNA-binding activity. Cancer Res 2005; 65: 9047-9055. (Pubitemid 41377397)
19. Sun X, Kanwar JR, Leung E, Lehnert K,Wang D, Krissansen GW. Gene transfer of antisense hypoxia inducible factor-1a enhances the therapeutic efficacy of cancer immunotherapy. Gene Ther 2001; 8: 638-645. (Pubitemid 32422058)
20. Zhang Q, Zhang ZF, Rao JY, Sato JD, Brown J, Messadi DV et al. Treatment with siRNA and antisense oligonucleotides targeted to HIF- 1a induced apoptosis in human tongue squamous cell carcinomas. Int J Cancer 2004; 111: 849-857. (Pubitemid 39096233)
21. Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 2002; 8: S55-S61. (Pubitemid 34297080)
22. Mabjeesh NJ, Post DE,Willard MT, Kaur B, Van Meir EG, Simons JW et al. Geldanamycin induces degradation of hypoxiainducible factor 1a protein via the proteosome pathway in prostate cancer cells. Cancer Res 2002; 62: 2478-2482. (Pubitemid 34462721)
23. Kurebayashi J, Otsuki T, Kurosumi M, Soga S, Akinga S, Sonoo H. A radicicol derivative, KF58333, inhibits expression of hypoxia-inducible factor-1a and vascular endothelial growth factor, angiogenesis and growth of human breast cancer xenografts. J Cancer Res 2001; 92: 1342-1351. (Pubitemid 34036899)
24. Welsh SJ, Williams RR, Birmingham A, Newman DJ, Kirkpatrick DL, Powis G. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1a and vascular endothelial growth factor formation. Mol Cancer Ther 2003; 2: 235-243.
25. Tan C, de Noronha RG, Roecker AJ, Pyrzynska B, Khwaja F, Zhang Z et al. Identification of a novel small-molecule inhibitor of the hypoxia inducible factor 1 pathway. Cancer Res 2005; 65: 605-612.
26. Mabjeesh NJ,Willard MT, Harris WB, Sun HY,Wang R, Thong H et al. Dibenzoylmethane, a natural dietary compound, induces HIF- 1a and increases expression of VEGF. Biochem Biophys Res Commun 2003; 303: 279-286. (Pubitemid 36338237)
27. Rapisarda A, Uranchimeg B, Sordet O, Pommier Y, Shoemaker RH, Melillo G. Topoisomerase I-mediated inhibition of hypoxiainducible factor 1: mechanism and therapeutic implications. Cancer Res 2004; 64: 1475-1482. (Pubitemid 38235619)
28. Yeo EJ, Chun YS, Cho YS, Kim J, Lee J-C, Kim M-S et al. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 2003; 95: 516-525. (Pubitemid 36511622)
29. Welsh S, Williams R, Kirkpatrick L, Paine-Murrieta G, Powis G. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1a. Mol Cancer Ther 2004; 3: 233-244. (Pubitemid 39193698)
30. Giaccia A, Siim BG, Johnson RS. HIF-1 as a target for drug development. Nat Rev Drug Discov 2003; 2: 803-811 (Pubitemid 37361812)
31. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-732. (Pubitemid 37328811)
32. Powis G, Kirkpatrick L. Hypoxia inducible factor- 1alpha as a cancer drug target. Mol Cancer Ther 2004; 3: 647-654. (Pubitemid 39193744)
33. Yeo EJ, Chun YS, Park JW. New anticancer strategies targeting HIF-1. Biochem Pharmacol 2004; 68: 1061-1069.
34. Belozerov VE, Van Meir EG. Hypoxia inducible factor-1: a novel target for cancer therapy. Anticancer Drugs 2005; 16: 901-909. (Pubitemid 41416080)
35. Escuin D, Kline ER, Giannakakou P. Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. Cancer Res 2005; 65: 9021-9028. (Pubitemid 41377394)
36. Wiedmann MW, Caca K. Molecularly targeted therapy for gastrointestinal cancer. Curr Cancer Drug Targets 2005; 5: 171-193. (Pubitemid 40694859)
37. Generali D, Berruti A, Brizzi MP, Campo L, Bonardi S,Wigfield S et al. Hypoxia-inducible factor-1a expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clin Cancer Res 2006; 12: 4562-4568. (Pubitemid 44297805)
38. Patiar S, Harris AL. Role of hypoxia-inducible factor-1a as a cancer therapy target. Endocr Relat Cancer 2006; 13: 61-75.
39. Powis G, Kirkpatrick L. Hypoxia inducible factor-1a as a cancer drug target. Mol Cancer Ther 2004; 5: 647-654. (Pubitemid 39193744)
40. Zhong H, Semenza GL, Simons JW, De Marzo AM. Upregulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. Cancer Detect Prev 2004; 28: 88-93. (Pubitemid 38448745)
41. Du Z, Fujiyama C, Chen Y, Masaki Z. Expression of hypoxiainducible factor 1alpha in human normal, benign, and malignant prostate tissue. Chin Med J 2003; 116: 1936-1939. (Pubitemid 38159901)
42. Fang J, Ding M, Yang L, Liu L-Z, Jiang B-H. PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis. Cell Signal 2007; 19: 2487-2497. (Pubitemid 47531929)
43. Karni R, Dor Y, Keshet E, Meyuhas O, Levitzki A. Activated pp60c-Src leads to elevated hypoxia-inducible factor (HIF)-1a expression under normoxia. J Biol Chem 2002; 277: 42919-42925. (Pubitemid 35285669)
44. Lou J, Zhou X, Weng Q, Wang D-d, Xia Q, Hu Y et al. XQ2, a novel TPZ derivative, induced G2/M arrest and apoptosis under hypoxia in non-small cell lung cancer cells. Biosci Biotechnol Biochem 2010; 74: 1181-1187.
45. Pauli RM, Strauss BS. Proliferation of human peripheral lymphocytes. Characteristics of cells once stimulated or restimulated by concanavalin A. Exp Cell Res 1973; 82: 357-366.